The global cervical cancer market for drugs and diagnostics was $11.3 billion in 2012 and is expected to grow from $11.6 billion in 2013 to $15.6 billion by 2018, a compound annual growth rate (CAGR) of 6.1%.
This report provides:
Download Report Overview
SCOPE OF THE STUDY
The scope of this study includes testing, prophylactics vaccines, screening tests and methods, and therapeutics markets for cervical cancers. The report also discusses current technologies, new technologies, cervical cancer incidence, and market projections and market share, along with latest trends and new developments.
ABOUT THE AUTHOR
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs involving target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology, and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.